| Entries |
| Document | Title | Date |
|---|
| 20090023759 | Quinazoline Derivatives as Inhibitors of EGF and/or erbB2 Receptor Tyrosine Kinase - A quinazoline derivative of the Formula I: | 01-22-2009 |
| 20090030021 | Quinazoline Derivatives and Therapeutic Use Thereof - Quinazoline derivatives represented by the general formula | 01-29-2009 |
| 20090082372 | Arylmethylene Substituted N-Acyl-Beta-Amino Alcohols - The present invention relates to arylmethylene substituted N-Acyl-β-amino alcohols of the formula I | 03-26-2009 |
| 20090105285 | PHARMACEUTICAL COMBINATIONS COMPRISING A MTOR INHIBITOR AND A RAF KINASE INHIBITOR - A pharmaceutical combination comprising an mTOR inhibitor and a Raf kinase inhibitor and its use. | 04-23-2009 |
| 20090170881 | NEW INHIBITORS OF HISTONE DEACETYLASE - This invention comprises the novel compounds of formula (I) | 07-02-2009 |
| 20090186911 | SULPHOXIMINE-SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNO-MODULATORS, THEIR PREPARATION AND USE AS MEDICAMENTS - The present invention relates to sulphoximine-substituted quinazoline derivatives of the formula (I), processes for their preparation and their use as a medicament for the treatment of various diseases. | 07-23-2009 |
| 20090221616 | QUINAZOLINE DERIVATIVES AS EGF AND/OR ERBB2 TYROSINE KINASE INHIBITORS - A quinazoline derivative of the Formula (I): wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm blooded animal such as man. | 09-03-2009 |
| 20090233950 | QUINAZOLINE DERIVATIVES - The invention concerns quinazoline derivatives of Formula I | 09-17-2009 |
| 20090306102 | 2-PYRIDIN-2-YL-QUINAZOLINE DERIVATIVES AS POTASSIUM CHANNEL MODULATING AGENTS FOR THE TREATMENT OF RESPIRATORY DISEASES - This invention relates to novel pyridinyl-quinazoline derivatives and their use as potassium channel modulating agents. Moreover the invention is directed to pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels. | 12-10-2009 |
| 20090306103 | PYRIDONECARBOXAMIDE DERIVATIVES USEFUL IN TREATING HYPER-PROLIFERATIVE AND ANGIOGENESIS DISORDERS - Pyridonecarboxamide derivatives, pharmaceutical compositions which contain the same and methods for treating hyper-proliferative disorders and angiogenesis disorders using the same. | 12-10-2009 |
| 20090325987 | QUINAZOLINEDIONE DERIVATIVES AS TRPA1 MODULATORS - The present invention provides Quinazolinedione derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1. | 12-31-2009 |
| 20100210671 | Quinazolinone T-Type Calcium Channel Antagonists - The present invention is directed to quinazolinone compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved. | 08-19-2010 |
| 20100249159 | RHO-KINASE INHIBITORS - Disclosed are compounds and derivatives thereof, their synthesis, and their use as Rho-kinase inhibitors. These compounds of the present invention are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease. | 09-30-2010 |
| 20100286175 | 2-(Pyridin-2-yl)-pyrimidines and Their Use for Controlling Harmful Fungi - The invention relates to 2-(pyridin-2-yl)-pyrimidine compounds of general formula (I) and their use for controlling pathogenic fungi and as plant protection products that, as an active constituent, contain compounds of this type: | 11-11-2010 |
| 20100298358 | Naphthamide Derivatives As Multi-Target Protein Kinase Inhibitors and Histone Deacetylase Inhibitors - Isolated compounds of formula I: | 11-25-2010 |
| 20110028498 | METHOD FOR EVALUATING PATIENTS FOR TREATMENT WITH DRUGS TARGETING RET RECEPTOR TYROSINE KINASE - The present invention provides a method of selection of a patient, who is a candidate for treatment with a RET drug, whereby to predict an increased likelihood of response to a RET drug. The invention provides a method for determining the sequence of RET. The method provides ARMS primers optimised for determining the sequence of RET. The invention also provides a diagnostic kit, comprising an ARMS primer. | 02-03-2011 |
| 20110112119 | AZABICYCLOOCTYL-QUINAZOLONE DERIVATIVES USEFUL AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS - This invention relates to novel azabicyclooctyl-quinazolinone derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances. | 05-12-2011 |
| 20110160232 | CERTAIN CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF - Certain chemical entities that modulate PI3 kinase activity, and chemical entities, pharmaceutical compositions, and methods of treatments of diseases and conditions associated with PB kinase activity are described. | 06-30-2011 |
| 20110195983 | QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS - The present invention relates to the use of a quinazolinone compound of the formula (I) wherein R | 08-11-2011 |
| 20110301184 | PHARMACEUTICAL COMBINATIONS COMPRISING A MTOR INHIBITOR AND A RAF KINASE INHIBITOR - A pharmaceutical combination comprising an mTOR inhibitor and a Raf kinase inhibitor and its use. | 12-08-2011 |
| 20120035194 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS - The present invention relates to compounds of formula (I), | 02-09-2012 |
| 20120101116 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS KINASES INHIBITORS AND METHODS OF USE THEREOF - The present invention is directed to novel quinolines and quniazolines, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof which are useful for the treatment of protein kinases mediated diseases and conditions. The compounds of this invention have a general Formula (I) wherein R | 04-26-2012 |
| 20120129875 | SUBSTITUTED QUINAZOLINES AS FUNGICIDES - The present invention relates to a compound of formula (I) wherein the substituents have the definitions as defined in claim | 05-24-2012 |
| 20120136014 | DIHYDROFOLATE REDUCTASE INHIBITORS - The present disclosure provides compounds of Formula I: | 05-31-2012 |
| 20120165352 | 6-AMINO QUINAZOLINE OR 3-CYANO QUINOLINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF - 6-amino quinazoline or 3-cyano quinoline derivatives, preparation methods and pharmaceutical uses thereof are disclosed. Specifically, the present disclosure discloses novel 6-amino quinazoline or 3-cyano quinoline derivatives presented by general formula (I), or tautomers, enantiomers, diastereomers, racemates or pharmaceutically acceptable salts thereof, or metabolites, metabolic precursors or prodrugs thereof, and their uses as treatment agents especially as protein kinase inhibitors, in which each substitutent group of general formula (I) is as defined in the specification. | 06-28-2012 |
| 20120184571 | QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS - The present invention relates to the use of a quinazolinone compound of the formula (I) wherein R | 07-19-2012 |
| 20120302587 | RHO-KINASE INHIBITORS - Disclosed are compounds and derivatives thereof, their synthesis, and their use as Rho-kinase inhibitors. These compounds are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease. | 11-29-2012 |
| 20130210844 | BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS - The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases. | 08-15-2013 |
| 20130261139 | USE OF A QUINAZOLINE COMPOUND IN PREPARING A MEDICAMENT AGAINST FLAVIVIRIDAE VIRUS - Disclosed is a use of a quinazoline compound of Formula I having 2,4-diaminoquinazoline as a parent nucleus in preparation of a medicament for treating diseases caused by flaviviridae infection, especially a use in combating Hepatitis C virus infection and Dengue fever virus infection. | 10-03-2013 |
| 20130267543 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF - The present invention relates to HSF activating compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof), and pharmaceutical Formulations thereof. In particular, the present invention provides compounds capable of facilitating HSF1 homotrimerization, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with irregular HSF1 activity. | 10-10-2013 |
| 20140045869 | DNA-PK INHIBITORS - The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. | 02-13-2014 |
| 20140045870 | 7-(Heteroaryl-Amino)-6,7,8,9-Tetrahydropyrido[1,2-A]Indol Acetic Acid Derivatives and Their Use as Prostaglandin D2 Receptor Modulators - The present invention relates to 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives of the formula (I), | 02-13-2014 |
| 20140080849 | Small Molecular Inhibitors of RAD51 Recombinase and Methods Thereof - The invention includes compositions comprising a selective small-molecule inhibitor of RAD51 recombinase and a pharmaceutically acceptable carrier. The invention further includes methods of treating or preventing cancer in a subject, comprising the step of administering to the subject the compositions contemplated within the invention. | 03-20-2014 |
| 20140221403 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY - The present invention relates to quinazoline containing zinc-binding moiety based derivatives of Formula (IV) below. | 08-07-2014 |
| 20140243361 | POLYMORPHS OF ARRY-380, A SELECTIVE HERB2 INHIBITOR AND PHARMACEUTICAL COMPOSITIONS CONTIANING THEM - Polymorphs of N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine are provided herein. Processes for preparing the polymorphs and pharmaceutical composition comprising the polymorphs are also disclosed. | 08-28-2014 |
| 20140275129 | TETRAHYDROISOQUINOLIN-2-YL-(QUINAZOLIN-4-YL)METHANONE COMPOUNDS - Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone derivatives represented by formula (I), pharmacologically acceptable salts thereof, and compositions containing such compounds are described. Methods for treating hyperproliferative disorders by administering the compounds are also described. 1,2,3,4-tetrahydroisoquinoline derivatives for making tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone compounds are also described. | 09-18-2014 |
| 20140288100 | GALACTOKINASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF ASSOCIATED DISEASES AND DISORDERS - Disclosed are inhibitors of human galactokinase of formula (1) that are useful in treating or preventing a galactokinase mediated disease or disorder, e.g., galactosemia. Also disclosed are a composition comprising a pharmaceutically acceptable carrier and at least one inhibitor of the invention, and a method of treating or preventing such disease or disorder in a mammal. Formula (I) | 09-25-2014 |
| 20140296266 | THERAPEUTIC COMPOUNDS - Compounds of formula I: | 10-02-2014 |
| 20140296267 | SOLID DISPERSIONS OF A ERB2 (HER2) INHIBITOR - A solid dispersion of N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and processes for preparing the solid dispersion are provided herein. Also, a pharmaceutical composition comprising a solid dispersion of N4-(4-([1,2,4]triazolo[1,5-α]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and uses thereof are provided herein. | 10-02-2014 |
| 20140309244 | NOVEL MICROBIOCIDES - The present invention provides compounds of formula (I) wherein R | 10-16-2014 |
| 20140315932 | QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS - The present specification relates to the use of a quinazolinone compound of the formula (I) wherein R | 10-23-2014 |
| 20140371246 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS - The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (I), | 12-18-2014 |
| 20140378483 | FGF Receptor (FGFR) Agonist Dimeric Compounds, Process for the Preparation Thereof and Therapeutic Use Thereof - The invention relates to novel heterocyclic compounds which are pyrazolopyridine derivatives that induce FGFR dimerization, having the general formula: M-L-M2 in which M and M2, which may be identical or different, each represent, independently of one another, a monomer unit M and L represents a linker group which links M | 12-25-2014 |
| 20150087663 | SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE - The invention relates to the preparation and use of new aminopyrimidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is mediated by the activity of the PI3K enzymes. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of disorders or diseases, such as disorders of immunity and inflammation in which PI3K enzymes play a role in leukocyte function, and hyperproliferative disorders associated with PI3K activity, including but not limited to leukemias and solid tumors, in mammals, especially humans. | 03-26-2015 |
| 20150126537 | BICYCLIC COMPOUNDS AS KINASES INHIBITORS - The present invention is directed to novel bicyclic compounds, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof. The compounds and compositions of the present invention have protein kinases inhibitory activities and are useful for the treatment of protein kinases mediated diseases and conditions. Novel bicyclic compounds disclosed herein include quinazolines and quinolines. | 05-07-2015 |
| 20150141442 | CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF - Certain chemical entities that modulate PI3 kinase activity, and chemical entities, pharmaceutical compositions, and methods of treatments of diseases and conditions associated with PB kinase activity are described. | 05-21-2015 |
| 20160002203 | QUINAZOLIN-4(3H)-ONE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF - The present disclosure relates to Quinazolin-4(3H)-one-Type Piperidine Compounds, such as those of Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R | 01-07-2016 |
| 20160039793 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS - The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (I), | 02-11-2016 |
| 20160136166 | TETRAHYDROISOQUINOLIN-2-YL-(QUINAZOLIN-4-YL)METHANONE COMPOUNDS - Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone derivatives represented by formula (I), pharmacologically acceptable salts thereof, and compositions containing such compounds are described. Methods for treating hyperproliferative disorders by administering the compounds are also described. 1,2,3,4-tetrahydroisoquinoline derivatives for making tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone compounds are also described. | 05-19-2016 |
| 20160175309 | POLYMORPHS OF ARRY-380, A SELECTIVE HER 2 INHIBITOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | 06-23-2016 |
| 20190144426 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | 05-16-2019 |
